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Natural products are small metabolites produced by living organisms with versatile chemical 
structures and diverse bioactivities. Bacteria are a rich but yet underexplored source of natural 
products. Natural product biosynthetic pathways encode a huge array of biosynthetic enzymes which 
can catalyze stereospecific and regiospecific modification of intermediates to produce complex 
natural products from simple precursors. The biosynthetic mechanisms underlying the production of 
natural products vary substantially. Cyanobactins are synthesized through the post-translational 
modification of precursor peptides and represent one of the most abundant natural product classes 
produced by cyanobacteria. Cyanobactins have a macrocyclic or linear structure with antimicrobial 
and cytotoxic bioactivities, although their ecological function is unclear. 
In this study, genome mining was used to catalog the genetic diversity of cyanobactin biosynthetic 
pathways from bacterial and archaeal genomes. Bioinformatic analysis of microbial genomes was 
used to identify cyanobactin biosynthetic pathways. New cyanobactin biosynthetic pathways were 
studied using a combination of bioinformatics, molecular biology, microbiology, biochemistry and 
structural chemistry. Bioinformatic predictions of cyanobactin biosynthetic gene clusters were 
performed based on DNA sequence data. Subsequently, candidate strains identified based on the 
predictions were grown in the laboratory and subjected to mass spectrometric analysis and 
heterologous expression. Novel cyanobactin natural products were discovered and the enzymes 
underpinning their biosynthesis were characterized.  
In the first part of the study, the muscoride biosynthetic gene cluster was described and a new 
muscoride variant was discovered. Two specific prenyltransferases from the muscoride biosynthetic 
gene cluster, which were biochemically characterized, catalyzed the regiospesific prenylation of the 
N- and C-termini of the linear polyoxazole muscorides. In the second part of the study, genome 
mining revealed a truncated cyanobactin biosynthetic gene cluster across the bacterial and archaeal 
domains for the production of structurally unusual cyanobactins. In the third part of the study, a 
regiospecific prenyltransferase was discovered, belonging to the anacyclamide cyanobactin pathway 
and catalyzing the N-prenylation of the tryptophan residue of the substrate peptide. 
The main aim of this work was to uncover novel cyanobactin biosynthetic gene clusters from bacteria 
and expand knowledge regarding the biosynthetic potential of cyanobactin pathways. The results 
from this thesis broaden the chemical diversity of the cyanobactin family and expand upon the 










Luonnonyhdisteet ovat molekyylejä, joita tuottavat kaikki elävät organismit. Näillä yhdisteillä on 
hyvin monipuolisia rakenteita ja bioaktiivisuuksia. Bakteerit ovat runsas, mutta silti suurelta osin 
kartoittamaton, lähde luonnonyhdisteille. Luonnonyhdisteiden biosynteesireitit koodaavat valtavan 
määrän biosynteettisiä entsyymejä, jotka katalysoivat erilaisia muokkausreaktioita tuottaakseen 
monimutkaisia rakenteita omaavia lopputuotteita. Syanobaktiinit ovat luonnonyhdistepeptidejä, jotka 
syntetisoidaan translaation jälkeisillä muokkausreaktioilla ja ne ovat yksi suurimmista 
syanobakteerien tuottamista luonnonyhdisteluokista. Syanobaktiinit ovat kemiallisilta rakenteiltaan 
syklisiä tai lineaarisia ja niillä on antimikrobisia sekä sytotoksisia bioaktiivisuuksia, vaikkakin niiden 
ekologinen rooli on vielä epäselvä. 
Tässä väitöskirjatutkimuksessa tutkittiin bioinformatiivisella genomilouhinnalla syanobaktiinien 
biosynteesireittien esiintyvyyttä bakteerien ja arkeonien genomeissa. Uusia syanobaktiinien 
biosynteesireittejä tutkittiin käyttämällä hyödyksi bioinformatiikkaa, molekulaarista biologiaa, 
mikrobiologiaa, biokemiaa sekä rakenteellista kemiaa. Syanobaktiineja tuottavat geenit ovat yleensä 
toistensa lähellä genomissa muodostaen geeniklusterin ja näiden geenien ennustukset tehtiin 
bakteerien DNA:n sekvensointitietoon perustuen. Kandidaattibakteerikantoja kasvatettiin 
laboratoriossa ja kasvatuksen jälkeen niitä tutkittiin massaspektrometrialla sekä heterologisella 
ekspressiolla, jotta saataisiin selville tuottavatko kyseiset bakteerikannat bioinformatiikalla 
ennustettuja luonnoyhdisteitä. Tässä työssä löydettiin uusia syanobaktiineja, sekä tunnistettiin näiden 
biosynteesissä tarvittavia entsyymejä.  
Työn ensimmäisessä osassa tunnistettiin kaksi biosynteettistä geeniklusteria luonnonyhdiste 
muskoridin tuottamiseen, sekä pystyttiin rakenteellisesti kuvaamaan uusi muskoridi variantti. 
Muskoridin biosynteettisessä geeniklusterissa on kaksi biokemiallisesti karakterisoitua spesifistä 
prenyylitransferaasientsyymiä, jotka katalysoivat lineaarisen muskoridin amino- ja 
karboksiterminaalien prenylaatiota. Työn toisessa osassa bioinformatiivisella genomilouhinnalla 
löydettiin bakteerien ja arkeonien genomeista tunnustettua lyhyempiä syanobaktiinien biosynteettisiä 
geeniklustereita, joiden ennustetut lopputuotteet ovat rakenteellisesti uudenlaisia syanobaktiineja. 
Työn kolmannessa osassa anasyklamidin biosynteettisesta geeniklusterista löydettiin spesifinen 
prenyylitransferaasientsyymi, joka liittää prenyyliryhmän substraattipeptidin tryptofaanin indolin 
typpiatomiin. 
Tämän väitöskirjatutkimuksen päätarkoituksena oli löytää ja karakterisoida uusia syanobaktiinien 
biosynteettisia geeniklustereita bakteereista sekä laajentaa tietämystä niiden biosynteettisesta 
potentiaalista. Tämän väitöskirjan tulokset ovat laajentaneet syanobaktiinien kemiallista 









1.1 Natural products 
 
Natural products are specialized metabolites that are produced by secondary metabolism in a wide 
variety of living organisms (Demain and Sanchez 2009; Jensen 2016; Katz and Baltz 2016). These 
secondary metabolites exhibit high structural and chemical diversity (Berdy 2005; Jensen 2016). They 
have different and usually essential functions, conferring a fitness advantage under specific 
environmental conditions, but they are not required for growth and reproduction under typical 
conditions (Jensen 2016; Katz and Baltz 2016; Walsh and Tang 2017). Secondary metabolites from 
microorganisms can also influence the survival and performance of other organisms (Demain and 
Sanchez 2009). Bacteria often produce secondary metabolites to fight against competing 
microorganisms in their natural habitat and for bacterial interactions (Baltz 2008; Li and Rebuffat 
2019). Natural products display a tremendous diversity of different bioactivities, and many 
pharmaceuticals and chemically synthesized drugs used today owe their origin to natural products 
(Demain and Sanchez 2009; Newman and Cragg 2016). Microorganisms are an abundant source of 
secondary metabolites, many of these being peptides with exotic structures (Donia et al. 2008; 
Arnison et al. 2013). Peptides are an important class of natural products which are used as antibiotics 
as well as anti-tumour and antiviral agents (Gurevich et al. 2018). At present, natural products or their 
derivatives, in general, represent an important source of novel therapeutic agents and pharmaceuticals 
(Newman and Cragg 2016; Ziemert et al. 2016). 
The major classes of natural products include peptides, polyketides, isoprenoid/terpenoid scaffolds, 
alkaloids, purines and pyrimidines, phenylpropanoid scaffolds, and flavonoids (Walsh and Tang 
2017). Natural products are relevant in nature as toxins (Du et al. 2019), antimicrobial agents (Lewis 
2017), siderophores (Kramer et al. 2019), and signaling molecules (Dutta et al. 2019) to name but a 
few examples. A principal driver for natural product research is the discovery of new natural 
products with the potential to act as drug leads. The increasing prevalence of antibiotic resistance 
along with a steady decrease in the discovery of novel antibiotics is threatening the prevention and 
treatment of infections caused by different pathogens worldwide (Mookherjee et al. 2020). To battle 
this crisis, the pharmaceutical industry is in constant need of new drug candidates. Bacteria are a 
voluminous source of natural products, many of which are potential drug leads, and microbial 
genomes are widely believed to encode new antimicrobial compounds with utility for the 
pharmaceutical industry and biotechnology (Newman and Cragg 2016). Key steps in natural product 
research include the identification of biosynthetic genes from producer organisms, which are usually 
clustered in close proximity to each other in the genome (biosynthetic gene clusters, BGSs); structural 
determination of the end-products from pathways; activity testing of the enzymes involved in the 
biosynthesis of natural products; and bioactivity testing of the compounds. The process of natural 
product discovery is highly likely to provide novel enzymes and molecules for use in biotechnology 








1.1.1 Biosynthesis of natural products  
 
Polyketides and nonribosomal peptides are synthesized by large specific multifunctional enzymes: 
polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) (Finking and Marahiel 
2004; Kopp and Marahiel 2007; Katz and Baltz 2016). Nonribosomal peptides and polyketides are 
synthesized by protein machinery via a thiotemplate chemical logic assembly line (Walsh and Tang 
2017). NRPSs are composed of modules, in turn, composed of domains that incorporate one selected 
amino acid into the polypeptide chain under synthesis (Katz and Baltz 2016). PKSs incorporate, in a 
processive manner, specific acyl-CoA units into a growing polyketide chain which is attached to the 
enzyme as a thioester until set free at the end of synthesis (Katz and Baltz 2016; Walsh and Tang 
2017). These type I PKSs also consist of modules which themselves are composed of enzymatic 
domains catalyzing a single step in the biosynthesis of the polyketide backbone (Katz and Baltz 
2016). Microbes frequently use hybrid nonribosomal-polyketide assembly lines for the biosynthesis 
of specialized metabolites (Walsh and Tang 2017). The other major PKS classes utilize a different 
assembly line logic (Walsh and Tang 2017). Peptides mediate diverse biological processes in all 
domains of life (Li and Rebuffat 2019) and are produced non-ribosomally (NRPSs) (Marahiel et al. 
1997) or through ribosomal synthesis and post-translational modification(s) (RiPPs) (Arnison et al. 
2013).  
 
1.1.2 Ribosomally synthesized and post-translationally modified peptides (RiPPs) 
 
Peptides, structurally diverse natural products, are now united into a single natural product class by 
their ribosomally synthesized and post-translationally modified peptide pathway (RiPP) (Arnison et 
al. 2013) apart from polyketides and non-ribosomal peptides. These peptides are found in all three 
domains of life: Bacteria, Eukarya and Archaea (Arnison et al. 2013). RiPPs encompass a vast 
genetic, functional and chemical space, and are related by a universal biosynthetic machinery shared 
by more than twenty known RiPP families (Arnison et al. 2013; Dunbar and Mitchell 2013; Ortega 
and van der Donk 2016; Hetrick and van der Donk 2017). RiPPs serve as a useful platform for novel 
natural products, unusual chemistry and new enzymology (Arnison et al. 2013; Ortega and van der 
Donk 2016; Hetrick and van der Donk 2017), and they exhibit many roles in the physiology and social 
behavior of microorganisms (Li and Rebuffat 2019). RiPPs have been shown in vitro and/or in vivo 
to be involved in communication, competition, and diverse physiological functions such as 
morphological development and biofilm formation (Li and Rebuffat 2019). Compounds resulting 
from this group of natural products are chemically highly diverse with a multitude of bioactivities 
(Arnison et al. 2013; Ortega and van der Donk 2016). The number of natural products belonging to 
the RiPP class is rapidly increasing, each adorned with unique chemical features (Arnison et al. 2013; 
Ortega and van der Donk 2016). The genetic coding of RiPP BGCs enables detailed structural 
predictions of the end-product (Skinnider et al. 2016), especially when the genes encoding for post-
translational modification (PTM) enzymes are annotated (Hetrick and van der Donk 2017). In general, 
RiPP gene clusters are small (Arnison et al. 2013; Ortega and van der Donk 2016; Santos-Aberturas 
et al. 2019). The genes encoding precursor peptides are often short and frequently unannotated in 
microbial genomes (Hetrick and van der Donk 2017), which makes them challenging to identify by 
genome mining (Santos-Aberturas et al. 2019). The discovery of numerous new RiPPs encoded 
within sequenced bacterial genomes may be possible by genome mining (Ortega and van der Donk 
2016; Skinnider et al. 2016), although at present the identification of undiscovered RiPPs, or even 
possibly complete RiPP families, is still an unsolved problem and challenge (Santos-Aberturas et al. 
2019).   
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RiPP BGCs can be recognized by the presence of specific modifying enzymes together with a 
precursor protein that incorporates sequence motifs distinctive to a particular RiPP family (Santos-
Aberturas et al. 2019). The end-product from a RiPP pathway can be accurately predicted from the 
genome sequence once the biosynthetic logic of the gene cluster is understood, which grants RiPP 
pathways potential for bioengineering (Velázquez and van der Donk 2011). RiPP BGCs are easily 
overlooked because of their small size (Hetrick and van der Donk 2017). However, the methods for 
RiPP discovery have been revolutionized due to the massive increase in publicly available genome 
sequence data (Bachmann et al. 2014; Ziemert et al. 2016). In addition to sequence data, advances in 
understanding biosynthesis and structural chemistry are important for the discovery of new RiPPs.  
RiPP BGCs comprise precursor gene(s) flanked by genes encoding post-translational enzymes which 
modify the precursor peptide (Arnison et al. 2013; Figure 1). The ribosomally translated precursor 
peptide consists of a leader peptide and a core peptide (Figure 1). Eukaryotic RiPPs often also contain 
an N-terminal signal sequence before the leader peptide that guides the peptide to specialized 
compartments of the cell for modification and secretion (Arnison et al. 2013). C-terminal recognition 
sequences after the core peptide(s) (i.e. follower peptide) are also occasionally present (McIntosh et 
al. 2009; Li and Rebuffat 2019; Figure 1) for cleavage and macrocyclization, for example, in 
cyanobactins and cyclotides (Arnison et al. 2013). The leader sequence is usually conserved, and the 
enzymes which modify the core typically recognize sequences in the leader (Arnison et al. 2013; 
Sardar et al. 2015). The leader peptides are believed to have numerous roles in post-translational 
modifications (Arnison et al. 2013), and the core peptide encoded into the precursor peptide is 
eventually produced to form the mature RiPP through post-translational modifications (Figure 1). 
The leader peptide might aid in the export of the core peptide outside from the cell and might also 
have a role in the activation, folding and stabilization of the bound modifying enzyme (Ortega and 
van der Donk 2016). The importance of the leader peptide has been demonstrated by deletion of the 
leader peptide abolishing core peptide modifications (Ortega and van der Donk 2016). A RiPP BGC 
can contain one or multiple precursor proteins, and one precursor protein can include multiple core 
peptides, which are all modified. In general, RiPP post-translational enzymes show high plasticity 
and substrate tolerance (Hudson and Mitchell 2018). As a demonstration of RiPP enzyme flexibility, 
a promiscuous prochlorocin biosynthetic enzyme from Prochlorococcus MIT9313 has been shown 
to have the capacity to transform 29 distinct gene-derived linear RiPPs to polycyclic RiPPs with 
remarkably varying ring topologies (Li et al. 2010).   
Post-translational modifications include, among others, miscellaneous cyclizations, dehydrations, 
rearrangements, terminal capping, hydroxylations, oxidations, phosphorylations, glycosylations, 
reductions, targeting moieties, as well as crosslinks between residues via oxazole, thiazole, 
lanthionine and disulfide bridges (Arnison et al 2013; Wang 2014). The end-products of RiPP 
pathways can achieve a high degree of chemical variety via extensive PTMs and structural variation 
encoded in the core (Arnison et al. 2013; Ortega and van der Donk 2016). All these factors endow 






Figure 1. General biosynthetic pathway for RiPPs. The gene encoding for the precursor peptide is flanked by 
genes encoding post-translational enzymes. The precursor peptide contains a core sequence that is 
transformed to the mature natural product via post-translational modifications. The figure has been adapted 
from Arnison et al. (2013) and Tan et al. (2019). 
 
1.1.3 Genome mining for new natural product biosynthetic pathways  
 
Natural product discovery, the search for new compounds from nature, can be divided into two 
distinct categories, known as structure-guided (top-down) and genome-guided (bottom-up) strategies. 
The structure-guided approach denotes natural product discovery without genomic data and no prior 
knowledge regarding the biosynthesis of the secondary metabolite in question (Luo et al. 2014). 
Structure-guided methods include comparative metabolomics profiling, fraction bioactivity testing, 
and structural characterization (Luo et al. 2014). The classic structure-guided approach for natural 
product discovery usually includes screening of crude extracts from natural sources, such as bacteria 
(Winter et al. 2011). However, this method is often problematic in the search for novel compounds 
because of the high probability to rediscover known natural products (Winter et al. 2011). In the 
genome-guided approach, genomics and bioinformatics are utilized in the search for new biosynthetic 
pathways of natural products in a process called genome mining (Luo et al. 2014; Ziemert et al. 2016). 
The rapid accumulation of genome sequence data in public databases combined with advancements 
in the understanding of natural product biosynthesis has enabled unprecedented opportunities for the 
discovery of novel natural products from a broad diversity of organisms (Challis 2008; Velázquez 
and van der Donk 2011; Bachmann et al. 2014; Jensen 2016; Ziemert et al. 2016; Kalkreuter et al. 
2020). The huge quantity of accessible genome data serves as the base for the examination and 
discovery of new specialized metabolites (Zerikly and Challis 2009) through comparative genomic 
approaches (Micallef et al. 2015). Although the diversity of secondary metabolites between and 
within different families is vast, the biosynthetic machineries are often conserved (Ziemert et al. 
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2016). Biosynthetic gene clusters within microorganisms encode enzymatic machineries that catalyze 
the production of chemically complex natural products, and many of these have been repurposed as 
pharmaceutical, agricultural, and manufacturing agents (Epstein et al. 2018).  
Genome mining is a powerful tool in the search for new secondary metabolites, as it predicts the 
biosynthesis of new natural products directly from genome sequences (Zerikly and Challis 2009) and 
has the theoretical potential to eliminate the rediscovery problem (discovery of already known 
compound) (Bachmann et al. 2014). Genome mining includes the examination of the sequenced 
genome of a microorganism to infer the presence of gene clusters involved in the production of novel 
natural products (Scheffler et al. 2013). Genome mining can be further combined with modern 
spectroscopy techniques, such as liquid chromatography-mass spectrometry (LC-MS) and 
quadrupole time-of-flight (Q-TOF), to identify the products of novel gene clusters (Scheffler et al. 
2013) which can eventually be used for heterologous expression and bioactivity testing (Micallef et 
al. 2014). In general, genome mining can be performed manually or using bioinformatic tools, such 
as antiSMASH (Weber et al. 2015), BAGEL3 (van Heel et al. 2013), and PRISM (Skinnider et al. 
2016). Genome mining specifically for RiPPs can also be performed either manually or using 
bioinformatic tools, such as RiPPquest (Mohimani et al. 2014), RODEO (Tietz et al. 2017), RiPPER 
(Santos-Aberturas et al. 2019) or the recently developed tool DeepRiPP (Merwin et al. 2020). 
RiPPquest combines bioinformatics and tandem mass spectrometry in the search for new RiPPs 
(Mohimani et al. 2014). DeepRiPP employs multiomics and machine learning for the automated 
discovery for novel RiPPs (Merwin et al. 2020). RODEO uses machine learning, heuristic scoring 
and hidden Markov model based analysis to predict and identify RiPP BGCs and precursor peptides 
(Tietz et al. 2017) Using RODEO, researchers have been able to expand the RiPP family of 
lassopeptides by an order of magnitude, as well as characterizing six novel lasso peptides, 
demonstrating it as a potent tool (Tietz et al. 2017). Advances in genome sequencing and 
bioinformatic tools have facilitated the discovery of thousands of BGCs encoding novel natural 
products. The field of natural product discovery is exhibiting considerable development in the 
genomic era (Epstein et al. 2018; Kalkreuter et al. 2020).   
 
1.2 Cyanobacteria and their specialized metabolites  
 
Cyanobacteria are one of the oldest and most successful life forms on earth, and they can be found in 
terrestrial, aerial, glacier, brackish, marine, and fresh water environments. They represent a 
specialized group of microorganisms with a high degree of versatility adapted to various ecological 
niches (Dixit and Suseela 2013). Cyanobacteria are able to produce an array of bioactive compounds, 
which have potential applications in many industries, including the pharmaceutical, cosmetic, and 
nutritional industries (Tan 2007; Demay et al. 2019). Cyanobacteria represent a source of different 
natural product classes, including peptides, alkaloids, polyketides, terpenes, fatty acids and UV-
absorbing compounds (Micallef et al. 2014; Demay et al. 2019). These specialized metabolites can 
be, among others, bioactive peptides or toxins (Burja et al. 2001; Demay et al. 2019).  
Fourteen major bioactivities have been listed for cyanobacterial specialized metabolites, including 
neurotoxicity, lethality, dermal toxicity, cytotoxicity, hepatotoxicity, antioxidant, anti-inflammatory, 
antiviral, antibacterial, anti-microalgal, antifungal, and antiprotozoal activities; as well as enzyme and 
protease inhibition activities (Demay et al. 2019). Cyanobacterial natural products are promising for 
drug discovery, and some of them have entered clinical trials, but thus far only one is in use as an 
actual therapeutic agent. In 2011 the United States Food and Drug Administration (FDA) approved 
brentuximab vedotin, or SGN-35 (Adcetris; Seattle Genetics), for the treatment of Hodgkin 
lymphoma (Deng et al. 2013). It is an antibody-drug conjugate derived from the cyanobacterial 
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compound dolastatin 10 (Senter and Sievers 2012; Deng et al. 2013; Figure 2). Examples of 
antimicrobial peptides from cyanobacteria include antifungal hassallidins (Vestola et al. 2014), 
antibacterial brunsvicamides (Müller et al. 2006), and the anti-cyanobacterial compound spiroidesin 
(Kaya et al. 2002) (Figure 2). The BGCs of antimicrobial bacteriocins have been demonstrated to be 
widespread in cyanobacteria by genome mining (Wang et al. 2011). There has been a considerable 
expansion (71 %) of new natural products reported from cyanobacteria since 2016 (Carroll et al. 
2019). The 48 novel compounds discovered from nine genera of cyanobacteria for the year 2017 
represents the highest number reported for this phylum since the initiation of the annual “Marine 
natural products” review article (Carroll et al. 2019). The currently established broad spectrum of 
cyanobacterial natural products includes over 1100 specialized metabolites with divergent chemical 










1.3 Cyanobactins  
 
Cyanobactins produced by cyanobacteria are a growing family of N-to-C macrocyclic and linear 
natural product peptides, which are synthesized through the post-translational modification of 
precursor proteins (Sivonen et al. 2010; Arnison et al. 2013; Leikoski et al. 2013). Ulicyclamide and 
ulithiacyclamide were the first cyanobactins reported four decades ago from the tunicate Lissoclinum 
patella (Ireland and Scheuer 1980). L. patella has an obligate cyanobacterial symbiont, and it was 
hypothesized that the symbiont, Prochloron, is actually responsible for the production of 
cyanobactins (Sings and Rinehart 1996). Two studies demonstrated that the cyanobacterium 
Prochloron is the biosynthetic source of patellamides isolated from the L. patella ascidian (Long et 
al. 2005; Schmidt et al. 2005). Long et al. (2005) used shotgun cloning of Prochloron genomic DNA 
introduced to E. coli and verified the heterologous expression of patellamides by LC-MS (Long et al. 
2005). Schmidt et al. (2005) used sequence data to identify the patellamide BGC and demonstrated 
that patellamides are synthesized using ribosomal machinery (Schmidt et al. 2005). The term 
cyanobactin was originally introduced in 2008 by Donia et al. to describe natural products that are 
macrocyclic, contain azoles and are produced through the cyanobactin biosynthetic pathway. At 
present, a growing number of compounds are emerging from the cyanobactin family that do not 
strictly adhere to the original definition of cyanobactins. Cyanobactin BGCs are widespread within 
cyanobacterial species (10–30 % of all cyanobacteria) (Donia et al. 2008; Leikoski et al. 2009; 
Leikoski et al. 2013), representing one of the largest natural product family produced by 
cyanobacteria (Schmidt and Donia 2009; Donia and Schmidt 2010).  
 
1.3.1 Chemical diversity of cyanobactins 
 
Cyanobactins were originally defined as macrocyclic peptides that contain azole (heterocyclic) 
residues (Donia et al. 2008; Sivonen et al. 2010). Anacyclamides, kawaguchipeptins (A and B), 
prenylagaramides, piricyclamides, scytodecamide and trikoramide A are to date the only 
cyanobactins that have no azol(in)es in their structures and consequently do not encode a 
heterocyclase within their BGCs (Ishida et al. 1996; Ishida et al. 1997; Leikoski et al. 2010; Donia 
and Schmidt 2011; Leikoski et al. 2012; Martins and Vasconcelos 2015; Parajuli et al. 2016; Crnkovic 
et al. 2019; Phyo et al. 2019). Cyanobactins frequently contain heterocycles or prenyl group(s), and 
occasionally contain both (Schmidt and Donia 2009; Gu et al. 2018). Most cyanobactins consist of 
L-amino acids, however, D-amino acids infrequently occur adjacent to a heterocyclized amino acid 
(Ishida et al. 1996; Milne et al. 2006; McIntosh et al. 2009; Gu et al. 2018).   
Short (3–5 amino acids) heavily modified linear cyanobactins have been reported from the 
cyanobacterial strains Microcystis aeruginosa PCC 9432 and Oscillatoria nigroviridis PCC 7112 
(Leikoski et al. 2013). Ulithiacyclamide (Ireland and Scheuer 1980; Figure 3) and piricyclamides 
(Leikoski et al. 2012) are to date the only cyanobactins containing intramolecular disulfide bridges. 
The cyanobactin BGC does not encode an enzyme for disulfide bridge formation, and it is suggested 
to be a spontaneous modification based on chemical proximity (McIntosh et al. 2009: Burkhart et al. 
2017) of thiol groups of cysteines in disulfide bridge containing cyanobactins. The extreme chemical 
diversity of cyanobactins originates from the characteristic genetic features of this class of natural 
products, including high variation in core peptide sequences, differing combinations of PTMs in 
biosynthesis, and diverging lengths of the mature cyanobactins from the pathways (Martins and 
Vasconcelos 2015; Burkhart et al. 2017). Examples of known cyanobactins and their chemical 




Figure 3. Chemical structures of selected cyanobactins.  
Genome mining aims to identify new cyanobactins through comparison of biosynthetic gene clusters 
(Schmidt and Donia 2009). Once the cyanobactin BGCs have been mapped, predictions for precursor 
peptide protease cleavage site(s) and core peptide sequences can be performed (Velázquez and van 
der Donk 2011). In cyanobactin BGCs, the most highly conserved genes encode the N- and C-
terminal proteases, a feature which can be utilized in the search for new cyanobactin pathways using 
BLAST (Donia and Schmidt 2011). However, certain cyanobactin pathways may remain 
unrecognized if the C-terminal protease is used for BLAST searching. The C-terminal protease might 
be absent from cyanobactin gene clusters, as has been shown in the case of scytodecamide (Crnkovic 
et al. 2019).  
The presence of cyanobactins outside the cyanobacterial phyla remains elusive. However, recent 
genome mining studies have reported three cyanobactin precursor peptides in the genera 
Streptomyces and Nocardiopsis (Poorinmohammad et al. 2019), seven cyanobactin BGCs in the 
genus Streptomyces (Belknap et al. 2020), and one cyanobactin BGC in Amycolatopsis alkalitolerans 
sp. nov. (Rao et al. 2020). However, in these studies, the BGCs were not identified and the precursor 








1.4 Cyanobactin biosynthesis 
 
1.4.1 General biosynthetic pathway 
 
Cyanobactins are ribosomally synthesized and post-translationally modified (RiPP) natural products. 
Cyanobactins are 3–20 amino acids in length, and the hypervariable core peptide sequences are 
completely variable, not just altered by point mutation (Leikoski et al. 2013; Martins and Vasconcelos 
2015; Sardar et al. 2015). Cyanobactins are defined as a natural product class by a shared biosynthetic 
logic (Arnison et al. 2013). They are produced by the post-translational modification of a short 
genetically encoded precursor peptide (Arnison et al. 2013). The precursor peptide is divided into 
leader, core and recognition sequences (Sardar et al. 2015). The core sequence is modified and excised 
to produce the mature natural product (Czekster et al. 2016; Gu et al. 2018). In many cases, the 
precursor peptide encodes multiple core peptides which all are transformed to mature natural products 
(Ortega and van der Donk 2016). Certain cyanobacterial strains encode cyanobactin pathways with 
multiple precursor peptides with varying cores, such as the pathway for cyanothecamides (Donia and 
Schmidt 2011; Houssen et al. 2012). The existence of multiple non-identical cores in the precursor is 
possible because of substrate promiscuity of cyanobactin tailoring enzymes and contributes to the 
enormous chemical diversity of cyanobactins (Arnison et al. 2013; Donia and Schmidt 2010; Sivonen 
et al. 2010). The core peptide is flanked by leader (usually around 40 residues) or follower sequences 
that are proteolytically cleaved and thereby discarded from the final product (Arnison et al. 2013).   
The canonical cyanobactin biosynthetic pathway includes the ribosomal synthesis of the precursor 
peptide (E-gene), followed by heterocyclization (D-gene) if the mature product contains heterocycles. 
This is followed by proteolytic cleavage of the leader sequence (A-gene), and 
cleavage/macrocyclization (G-gene) (Figure 4; Czekster et al. 2016; Gu et al. 2018). The size of a 
cyanobactin BGC is approximately 8–19 kb in length (Martins and Vasconcelos 2015), and the gene 
organization is not strictly conserved (Sivonen et al. 2010). Additional tailoring enzymes are often 
present in cyanobactin biosynthetic pathways, including prenyltransferases, oxidases, and 
methyltransferases (Hao et al. 2016; Sardar et al. 2017; Gao et al. 2018; Crnkovic et al. 2019). 
Recently, a novel linear cyanobactin, scytodecamide, was demonstrated to be amidated in the C-
terminus by the amidotransferase ScdTA (Crnkovic et al. 2019; Figure 3). These additional enzymes 
usually, but not always, catalyze late-stage reactions in cyanobactin biosynthesis (Martins and 




Figure 4. Schematic depiction of canonical cyanobactin pathway represented by the patellamide (pat) 
pathway. The figure has been adapted from Schmidt et al. (2005) and Gu et al. (2018). 
 
Cyanobactin enzymes have a natural ability for plasticity enabling them to process several substrates, 
but the end-product(s) of the pathways is usually specific (Martins and Vasconcelos 2015; Czekster 
et al. 2016; Gu et al. 2018). Identical enzymes thus modify hypervariable core peptides within 
cyanobactin pathways (Sardar et al. 2015). The relaxed substrate selectivity of cyanobactin pathways 
was shown by Tianero et al. (2012) who used the tru pathway to generate cyanobactin mutants. In 
addition to mutations to the core peptide, non-proteogenic amino acids were introduced to the core 
and the products produced (Tianero et al. 2012). The PTM enzymes were tolerant to changes made 
to the core (Donia et al. 2006; Tianero et al. 2012), suggesting that cyanobactin pathways are ideal 
for bioengineering using synthetic biology (Martins and Vasconcelos 2015; Sardar et al. 2015). 
Recognition sequences (RSs) are short sequences encoded into the precursor protein that guide 
enzymes that modify the core (Oman and van der Donk 2010) but are not part of the final natural 
product (Gu et al. 2018). Enzymes bind to RSs and therefore focus their biosynthetic efforts on a 
single gene product (Gu et al. 2018). Cyanobactin core peptides are hypervariable, but the leader 
sequences including recognition sequences are to some extent conserved. The heterocyclase (D-
protein) recognizes RSI, while RSII and RSIII guide the activities of the protease (A-protein) and 
macrocyclase (G-protein), respectively (Lee et al. 2009; Figure 4). If the precursor peptide encodes 
more than one core, each one is sandwiched by N-terminal (RSII) and C-terminal (RSIII) RSs which 
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can comprise four or five amino acids (Martins and Vasconcelos 2015; Figure 4). It is unknown which 
recognition elements are required for the activity of the oxidase and prenyltransferase (Koehnke et 
al. 2015). The prenyltransferase is thought to act on the released product, and therefore no RSs would 
be needed for the catalytic activity of a cyanobactin prenyltransferase. 
The canonical cyanobactin pathway encompasses two proteases: PatA and PatG. Leikoski et al. 
(2013) reported linear cyanobactins, aeruginosamide A & B and viridisamide A, possessing both 
proteases (A and G) within their BGCs. The C-terminal protease (G-protein) in the linear cyanobactin 
pathway (age and vir) linearizes and hydrolyzes instead of macrocyclization (Leikoski et al. 2013; 
Sardar et al. 2017). A better understanding of the enzyme mechanisms involved in the biosynthesis 
of the evermore expanding cyanobactin class of natural products would provide new interesting 
(bio)chemistry and insights to the concept of cyanobactin BGC. With the progress of genome mining 
studies, unusual cyanobactins are highly likely to be discovered in the near future expanding the scope 
of the biosynthetic potential of cyanobactin BGCs.  
The minimal set of genes needed for cyanobactin biosynthesis and present in cyanobactin gene 
clusters includes genes encoding the precursor peptide, two short conserved hypothetical proteins, 
and two proteases (Donia and Schmidt 2010). The prenyltransferase is present in most cyanobactin 
BGCs, including those whose end-product is not prenylated (Schmidt and Donia 2009; Sivonen et al. 
2010). Scytodecamide from Scytonema sp. UIC 10036 is a novel linear cyanobactin featuring N‐
terminal N‐methylation and C‐terminal amidation (Crnkovic et al. 2019; Figure 3), which are both 
unprecedented PTMs in cyanobactin biosynthesis. Scytodecamide is a unique linear cyanobactin 
decorated only with the N-terminal protease (A-protein) and missing the G-protein completely from 
its BGC, suggesting that the concept of minimal cyanobactin BGC needs to be redefined. What is 
minimal to one cyanobactin pathway might not be minimal for another. Genome mining leading to 
the discovery of structurally novel cyanobactins expands the enzymatic machinery of cyanobactin 
biosynthesis.  
 




The canonical cyanobactin gene cluster encompasses two proteases which are responsible for 
cleavage of the precursor peptide and cyclization of the mature product, PatA and G -homologs (Lee 
et al. 2009; Donia and Schmidt 2010; Sivonen et al. 2010). They are paralogous enzymes and have 
relatively high sequence similarity (~ 40 %) (Lee et al. 2009; Agarwal et al. 2012; Czekster et al. 
2016). These proteases were first characterized when the pat gene cluster was discovered (Schmidt 
et al. 2005). The PatA homolog is responsible for the proteolytic cleavage of the N-terminal, while 
the PatG homolog catalyzes cleavage of the C-terminal recognition sequence together with 
simultaneous cyclization (Lee et al. 2009). The PatA homolog recognizes the G(L/V)E(A/P)S 
recognition sequence at the N-terminus, and the PatG homolog recognizes the AYDG(E) recognition 
sequence at the C-terminus (Lee et al. 2009; Figure 4). The N-terminal G(L/V)E(A/P)S recognition 
sequence is not strictly conserved and varies between cyanobactin pathways, for instance, in the case 
of cyanothecamides with the non-canonical flanking sequences GFEAP and SNCIG (Houssen et al. 
2012). The PatA and PatG -homologs are both subtilisin-like serine proteases (Oman and van der 
Donk 2010), and they both have a domain of unknown function (DUF) (Lee et al. 2009; Agarwal et 
al. 2012). Both proteases recognize the RSII and RSIII (Ortega and van der Donk 2016; Figure 4), 
and eventually the 50–150 amino acid long precursor protein is excised and modified to form the 
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mature product (Donia and Schmidt 2010; Sivonen et al. 2010). The catalytic triad of the PatA 
protease domain is composed of Asp23-His58-Ser218 (Agarwal et al. 2012). Two disulfide bridges 
are present in the PatA protease domain, between Cys156 and Cys158, and between Cys258 and 
Cys269, respectively (Agarwal et al. 2012; Houssen et al. 2012). 
Most cyanobactins are macrocyclic via ligation by peptide bond of their C- and N-termini, and not 
via amino acid side chains like many other macrocyclic secondary metabolites (Agarwal et al. 2012; 
Czekster et al. 2016; Gu et al. 2018). PatG includes a protease domain, an oxidase domain, and N- 
and C-terminal DUFs (Gu et al. 2018; Figure 4). The catalytic triad of the PatG protease domain is 
composed of Asp548-His618-Ser783 (Agarwal et al. 2012). PatG functions via a transamidation 
mechanism where the reactive-site Ser of PatG forms an enzyme-substrate tetrahedral intermediate 
with the evanescence of the C-terminal recognition sequence (Lee et al. 2009). An exception to this 
rule lies in the age pathway where the PatG homolog (AgeG) linearizes and hydrolyzes instead of 
macrocyclization resulting in a linear product (Leikoski et al. 2013; Sardar et al. 2017). PatG has 
value as a biotechnological tool as a macrocyclase because it has high substrate tolerance, but the C-
terminal recognition sequence must be present (Lee et al. 2009). Additionally, the substrate is required 
to have at least one proline or thiazoline and is between 6–11 amino acid residues in size in order for 
PatG to catalyze macrocyclization efficiently (Koehnke et al. 2012). However, the proline/thiazoline 
requirement has been bypassed using double cysteine and triazole, creating two synthetic routes for 
the PatG macrocyclase (Oueis et al. 2017). The promiscuity of the PatG macrocyclase has been 
demonstrated with unnatural substrates producing patellamide-like macrocyclic compounds (Oueis 
et al. 2015). The enzyme substrate specificity of the OscG cyanobactin macrocyclase from the 
oscillacyclamide pathway from Oscillatoria sp. PCC 6506 was tested for 19 linear peptide substrates 
(Alexandru-Crivac et al. 2017). Compared to PatG, OscG was shown to possess less rigorous 
recognition determinants, wider substrate tolerance, and the ability to process longer substrates 




Many natural product RiPPs contain Thr-, Ser- and Cys-derived heterocycles (McIntosh et al. 2009; 
Arnison et al. 2013), and the heterocyclization (also known as cyclodehydration) of these amino acid 
residues is a common modification in cyanobactin pathways (Koehnke et al. 2015; Martins and 
Vasconcelos 2015). Peptide heterocycles add chemical diversity, reduce polarity and increase 
conformational stability in peptides (Czekster et al. 2016). Heterocyclic structures are formed when 
the side-chain hydroxyl of Thr, Ser or Cys or thiol attacks the carbonyl carbon of the adjoining amino 
acid yielding methyloxazoline, oxazoline, or thiazoline, respectively (McIntosh et al. 2009). The 
oxidized derivatives of these structures are named methyloxazole, oxazole and thiazole, respectively 
(McIntosh et al. 2009). Cyanobactins usually contain oxazoline and thiazoline structures, or their 
oxidized derivatives oxazoles and thiazoles (Sivonen et al. 2010; McIntosh and Schmidt 2010; 
Velázquez and van der Donk 2011; Gu et al. 2018). Heterocyclases recognize the RSI binding site 
and catalyze the alterations of one or more serine, threonine or cysteine, into the equivalent azoline 
(McIntosh and Schmidt 2010). When the RSI is present, substrate peptides are effectively 
heterocyclized, while in the absence of RSI, heterocyclization is very inefficient or totally abolished 
(Sardar et al. 2015). Cyanobactin pathways which lack the heterocyclase, RSI is absent from the 
precursor peptide (Gu et al. 2018). Adding RSI to cyanobactin precursor peptides, which originally 
lack RSI, allows access to the element and enables heterocyclization (Sardar et al. 2015). LynD 
anchors the substrate peptide by binding a conserved region within the leader sequence of PatE 
(Koehnke et al. 2015). The leader peptide of the substrate also forms contacts with the LynD catalytic 
domain stabilizing a loop within the active site (Koehnke et al. 2015). Heterocycles are not contiguous 
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in the cyanobactins reported to date but are instead interspersed in the macrocycle occurring singly 
(McIntosh et al. 2009; Sivonen et al. 2010; Martins and Vasconcelos 2015).  
Many cyanobactins include a heterocycle at the C-terminus of the core peptide (either proline or 
azol(in)e derived from cysteine, serine, or threonine) (Donia and Schmidt 2010; Donia and Schmidt 
2011; Leikoski et al. 2013). Heterocyclases require ATP and Mg2+ for their activity, and they share 
the YcaO domain as a catalytic unit (Dunbar et al. 2012). The cyanobactin heterocyclase has two 
domains in addition to YcaO: an E1-like domain and a substrate recognition domain (RiPP 
recognition element, RRE) (Burkhart et al. 2015; Gu et al. 2018; Figure 4). YcaO family 
heterocyclases are relatively widespread in cyanobactin gene clusters, suggesting that 
heterocyclization offers a favorable change in the chemical construction of cyanobactins (Burkhart et 
al. 2017). The TruD cyanobactin heterocyclase was shown to be an adenylase and catalyze cysteine 
heterocyclization in strict order from the C- to N-terminus (Koehnke et al. 2013). The leader peptide 
can be discarded and TruD will act on a single specific cysteine (Koehnke et al. 2013). 
Heterocyclization most likely occurs as the first step of cyanobactin biosynthesis for the unmodified 
precursor. MicD, a cyanobactin heterocyclase from Microcystis aeruginosa, can heterocyclize both 
cysteines and threonines (Ge et al. 2019). Cysteines are heterocyclized before threonines from the C- 




The oxidase enzyme catalyzes the formation of (methyl)oxazoles and thiazoles from 
methyloxazolines, thiazolines, and oxazolines which are made by the heterocyclase (Czekster et al. 
2016). The cyanobactin oxidase does not seem to compose a complex with the heterocyclase, but is 
either found as a freestanding protein or fused together as an oxidase domain with the macrocyclase 
enzyme and a DUF (G-protein) (Donia and Schmidt 2011; Gao et al. 2018). The ThcOx oxidase from 
Cyanothece sp. PCC 7425 catalyzes thiazoline rings oxidation to thiazoles with FMN as a cofactor, 
but this enzyme is unable to use linear peptides as a substrate (Houssen et al. 2014). An enzyme from 
A. platensis homologous enzyme to ThcOx, ApOx, was able to oxidize thiazoline into thiazole on 
linear and macrocyclic cyanobactin precursors (Houssen et al. 2014). ThcOx consists of a C-terminal 
FMN binding the nitroreductase catalytic domain and two RRE domains at the N-terminus (Bent et 
al. 2016). Recently, ThcOx was shown to convert thiazolines to thiazoles regardless of the presence 
of the leader peptide, and the reaction was shown to be faster and more efficient on the leaderless 
substrate (Gao et al. 2018). Oxidation by ThcOx proceeds in a defined order from the N- to C-
terminus (Gao et al. 2018). Since the order does not depend on the leader, it is a feature of the enzyme 
and core sequence (Gao et al. 2018). Cyanobactin oxidases can catalyze oxidation on linear and 
macrocyclic substrates, and they could therefore be used as flexible enzymes in biotechnological 




Prenylation is a widespread modification in nature. Prenylation enhances the lipophilicity of natural 
products and increases their affinity for biological membranes (Botta et al. 2005; Wong et al. 2018). 
According to current understanding, F-type cyanobactin prenyltransferases act at the final step of 
biosynthesis (McIntosh et al. 2011). Cyanobactin prenylation is catalyzed by ABBA 
prenyltransferases (Hao et al. 2016; Gu et al. 2018). Two cyanobactin prenyltransferases have been 
crystallized, the inactive PatF (Bent et al. 2013) and active PagF (Hao et al. 2016; Figure 5 A), 
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demonstrating the ABBA fold. The structure of the ABBA prenyltransferase is composed of a central 
barrel of 10 antiparallel β-strands surrounded by α-helices (Kuzuyama et al. 2005; Metzger et al. 
2009; Bonitz et al. 2011). The central barrel forms a catalytic cavity where substrate binding and 
catalysis occurs (Kuzuyama et al. 2005; Metzger et al. 2009; Hao et al. 2016). The sidechains of 
catalytic amino acid residues stick into the barrel which control the donor substrate DMSPP (or 
DMAPP) (Figure 5 A; Hao et al. 2016), which enables substrate prenylation (Figure 5 B). The 
cyanobactin prenyltransferases have a broad substrate selectivity and they accept a wide range of 
macrocyclic and linear peptide substrates (Hao et al. 2016; Gu et al. 2018). The plasticity of 
cyanobactin prenyltransferases makes them valuable catalysts in synthetic biology creating structural 
diversity to a wide array of compounds.  
 
 
Figure 5. A) PagF cyanobactin prenyltransferase (PDB: 5tu6) in complex with DMAPP demonstrating the 
ABBA-fold (Hao et al. 2016). B) Cyclic peptide substrate (INPYLYP) in complex with DMSPP (Hao et al. 
2016). The Tyr-residue (colored in cyan) is the prenyl (colored in magenta) acceptor. Figures were created 
with Pymol based on PDB structures.  
 
The catalytic activity of a cyanobactin prenyltransferase does not depend on the recognition sequence 
in the precursor protein, and therefore it has relatively relaxed substrate selectivity (Hao et al. 2016).  
Cyanobactin prenyltransferases are known for their promiscuous substrate selectivity. Nevertheless, 
they are highly specific regarding the donor substrate and the regio/stereo positioning of the prenyl 
relative to the peptide substrate (Gu et al. 2018). Owing to these characteristics, they could be useful 
for the prenylation of particular residues of divergent peptide substrates (Gu et al. 2018). 
Prenyltransferases from cyanobactin pathways can catalyze forward and reverse prenylation on cyclic 
and linear substrates.  
The trunkamide cyanobactin biosynthetic gene cluster encodes the TruF1 and TruF2 enzymes, and 
trunkamide is bisprenylated on threonine and serine (Donia et al. 2008; McIntosh et al. 2011). 
Heterologous expression studies have been carried out by Tianero et al. (2016) to demonstrate the 
activities of the potential prenyltransferases TruF1 and TruF2. The genes encoding TruF1 and TruF2 
were knocked out individually or together, and it was shown that TruF1 is individually responsible 
for the prenylation in the tru pathway while TruF2 is a nonprenylating homolog. The deletion of 
TruF1 led to the production of macrocyclic peptides without prenyl moieties (Tianero et al. 2016). 
The TruF1 prenyltransferase O-prenylates Thr, Tyr and Ser on cyclic or linear peptide substrates (Hao 
et al. 2016). 
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Prenylagaramides are forward O-prenylated on Tyr by PagF (Donia and Schmidt 2011). 
Aestuaramides are reverse O-prenylated on Tyr by LynF (McIntosh et al. 2011; McIntosh et al. 2013). 
Reverse prenylated Tyr intermediates can undergo a spontaneous Claisen rearrangement, yielding a 
forward C-prenylated moiety, even without an enzyme (McIntosh et al. 2013). PagF O-prenylates 
Tyr in forward orientation (Hao et al. 2016). The recently discovered sphaerocyclamide is forward 
O-prenylated on Tyr by the SphF prenyltransferase (Martins et al. 2018; Figure 7).  
Croissamide is reverse N-prenylated on Trp (Iwasaki et al. 2018). The biosynthetic gene cluster has 
not been described, but the structure suggests that croissamide is a cyanobactin. Recently, trikoramide 
from Symploca hydnoides was reported with a C-prenylated cyclotryptophan in forward orientation 
(Phyo et al. 2019; Figure 3). Kawaguchipeptin A produced by Microcystis aeruginosa NIES-88 is a 
cyclic peptide and C-bisprenylated on two Trp residues in forward orientation (Ishida et al. 1996; 
Figure 3). The kawaguchipeptin gene cluster has been identified and, heterologously expressed, and 
it has been shown that the bisprenylation of Trp is catalyzed by the prenyltransferase KgpF encoded 
in the gene cluster (Parajuli et al. 2016). The prenylation by KgpF was shown in vitro on several 
linear and cyclic substrates using DMAPP as a donor substrate (Parajuli et al. 2016). The 
stereospecificity of forward C-prenylation by KgpF has been confirmed using Fmoc-protected Trp 
(Okada et al. 2016).   
A smaller proportion of cyanobactins are linear by structure, and are reverse prenylated on the N-
terminus and methylated on the C-terminus (Leikoski et al. 2013; Figure 3). This linear peptide 
termini protection is carried out by the bifunctional enzyme AgeMTPT (Sardar et al. 2017). Leikoski 
et al. (2013) have hypothesized that the N- and C-termini prenylated natural product peptide 
muscoride (Nagatsu et al. 1995) might be the product of a cyanobactin BGC (Leikoski et al. 2013).  
Piricyclamide cyanobactins from Microcystis aeruginosa PCC 7005 have been suggested to be 
geranylated instead of prenylation by prenyltransferase PirF (Leikoski et al. 2012). Later this enzyme 
PirF has been shown to be a geranyltransferase catalyzing forward O-geranylation of Tyr, an 
unprecedented post-translational modification in cyanobactin biosynthesis (Morita et al. 2018). 
Mutagenesis of only one amino acid (Phe222 to Ala222) residue in the binding pocket of the PirF 
ABBA prenyltransferase alters the donor specificity from prenyl to geranyl (Estrada et al. 2018). This 
might be due to amino acid sidechains sticking into the catalytic chamber of the enzyme. When there 
is Phe at the catalytic site, it possibly prevents geranyl substrate binding because of space restriction 
(Figure 6). These high plasticity characteristics promote cyanobactin prenyltransferases as valuable 





Figure 6. Structural alignment of PirF geranyltransferase (PDB: 6pgm) and PagF prenyltransferase (PDB: 
5tu6). The peptide substrate (INPYLYP) is coloured in green. The diphosphate group of DMAPP is shown in 
brown and the prenyl group of DMAPP in green. 
 
1.5.5 Proteins and domains of unknown functions in cyanobactin BGCs  
 
Cyanobactin pathways encode proteins with unknown functions as well as domains of unknown 
functions (DUFs). The genes encoding for B- and C-proteins occur in cyanobactin gene clusters, as 
do homologous C-terminal DUFs of A- and G-proteins (Lee et al. 2009; Agarwal et al. 2012; Figure 
4), but their functions are unknown. The B- and C-proteins are short proteins without recognized 
functions and no resemblance to proteins associated with known functions (Gu et al. 2018). Since 
DUFs are conserved throughout cyanobactin pathways, they are likely to have an operational role in 
biosynthesis (Sikandar and Koehnke 2019). Because DUFs from PatA and PatG are homologous, it 
has been suggested that these domains could form heterodimers of PatA and PatG through Zn2+ -
mediated dimerization, which might be essential for the in vivo -activity of these proteins (Sikandar 
and Koehnke 2019). Such a complex could possibly reduce precursor peptide degradation by 
substrate channeling (Sikandar and Koehnke 2019). Epimerization has been suggested as a possible 
role for DUF, but the epimerization to the D-form has been noted to be most likely spontaneous and 
non-enzymatic (Wipf et al. 1998; Milne et al. 2006: McIntosh et al. 2009; Koehnke et al. 2014). It is 
possible that epimerization enables the macrocycles to accept the thermodynamically preferred form 
(Gu et al. 2018). The structure of the DUF of PatG was determined, but no binding between precursor 
peptide and this domain was shown (Mann et al. 2014). The fold of the DUF was new but yielded no 
insights regarding its potential function (Mann et al. 2014). The PatG -DUF has one disulfide bridge 
between Cys1136 and Cys1142 and a single Zn2+ ion in the part of the domain that was characterized 
(Mann et al. 2014). The heterologous expression of patellamides demonstrated that PatB and PatC 
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are nonessential in patellamide biosynthesis (Donia et al. 2006). Nevertheless, these proteins and 
domains are universally found in cyanobactin BGCs, and they therefore presumably have important 
roles in cyanobactin biosynthesis. 
 
1.6 Ecological role of cyanobactins and bioactivity 
 
The ecological role of cyanobactins is not fully understood. Macrocyclization is a common 
modification in cyanobactins, supposedly because of the advantages that macrocycles provide in 
activity, membrane permeability and stability properties compared to their linear counterparts 
(Agarwal et al. 2012; Koehnke et al. 2012). Cyanobactins have selective metal chelating properties, 
and they might therefore have a role in metal transport, storage or detoxification (Bertram and 
Pattenden 2007; Houssen and Jaspars 2010; Bauermeister et al. 2019). Cyanothecamides were 
detectable after Cyanothece PCC 7425 was subjected to heat shock, suggesting that the expression of 
these cyanobactins might be due to stress responses (Houssen et al. 2012; Figure 7). Trikoramide was 
shown to be cytotoxic against AML2 and MOLT-4 cancer cell lines (Phyo et al. 2019; Figure 3). 
Wewakazole B was shown to be cytotoxic against human H460 lung cancer cells and human MCF7 
breast cancer cells (Lopez et al. 2016; Figure 7). Ulithiacyclamide showed potent cytotoxic activity 
against L1210 murine leukemia cells and it was suggested that the efficacy of this cyanobactin was 
associated with the intramolecular disulfide bridge (Shioiri et al. 1987; Figure 3). The cytotoxic effect 
of ulithiacyclamide was decreased when the compound was treated with dithiothreitol (DTT) to 
reduce the disulfide bridge to prevent the correct conformation of the molecule (Shioiri et al. 1987). 
Further development of ulithiacyclamide was, however, stopped because of its high toxicity (Houssen 
and Jaspars 2010). Bisprenylated patellin 2 might inhibit potassium channels by blocking (Tianero et 
al. 2016). Antibacterial cyanobactins include the prenylated sphaerocyclamide against Halomonas 
aquamarina (CECT 5000) (Martins et al. 2018; Figure 7), muscoride A against Bacillus subtilis 
(Nagatsu et al. 1995; Figure 13), and kawaguchipeptins A (Figure 3) & B against Staphylococcus 
aureus at minimal inhibition concentrations (MIC) of 1 μg/mL (Ishida et al. 1997). Whether these 
bioactivities are associated with the ecological roles of cyanobactins remains an enigma (Gu et al. 
2018). Despite limited understanding regarding the bioactivity and ecological role of cyanobactins, 
they still show promise in synthetic biology applications. The PTM enzymes from cyanobactin 




Figure 7. Selection of bioactive cyanobactins. 
 
1.7 Antimicrobial peptides (AMPs) 
 
Antibiotic resistance is a global health threat, especially owing to the lack of new antimicrobial drugs 
(Tossi et al. 2000; Hassan et al. 2012: Mookherjee et al. 2020). As a consequence, new therapeutic 
agents are urgently needed which would be less likely to cause antibiotic resistance. Antimicrobial 
peptides (AMPs) represent attractive candidates for the development of new antimicrobial agents for 
multidrug resistant bacteria (Ageitos et al. 2017). An antimicrobial peptide (AMP) is an agent that 
kills microorganisms or inhibits their growth. One indisputable function of RiPPs is related to AMPs 
(Hudson and Mitchell 2018), which operate as chemical weapons in competition and defense (Li and 
Rebuffat 2019). AMPs are important factors in the innate immunity in multicellular eukaryotes 
(Zasloff 2002), and in microorganisms, AMPs are generally considered to be chemical weapons 
allowing microbes to eradicate rivals from other species fighting for the same ecological niche 
(Hassan et al. 2012; Li and Rebuffat 2019). Regardless of their biological origin, all AMPs include a 
linear or cyclic structure and are small in size (7–100 amino acids) (Ageitos et al. 2017). Most 
naturally occurring AMPs have an amphipathic structure and are cationic (Lai and Gallo 2009). 
Usually AMPs are co-expressed as groups that act in synergy, although this depends on the cell (Lai 
and Gallo 2009).   
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AMPs can be broadly divided into four groups: (1) linear α-helix structure peptides with amphipathic 
properties; (2) β-sheet peptides often stabilized by disulfide bridges; (3) extended peptides with a 
relatively high amount of specific amino acids (most often Arg, Gly, Pro, Trp, and/or His); and (4) 
peptides possessing one or more D-amino acids or modified amino acid(s) in their structure (Lai and 
Gallo 2009; Ageitos et al. 2017; Mookherjee et al. 2020; Figure 8).  
 
Figure 8. Structures of selected AMP´s. 1) α-helical LL-37 (PDB: 2FBS); 2) Human beta-defensin-2, where 
disulfide bridges are highlighted as light brown (PDB: 1FQQ); 3) Indolicidin, which is unusually rich in 
tryptophan and proline (PDB: 1G89); 4) Gramicidin B, where D-amino acids are highlighted in cyan (PDB: 
1JO3). All structures were drawn using PyMol based on PDB structures. 
 
1.7.1 Disulfide bridge formation 
 
The amino acid cysteine is able to form covalent intra -and inter molecular disulfide bridges through 
its reactive side chain thiol group (SH) (Fass and Thorpe 2018). Disulfide bond formation is a 
widespread post-translational covalent modification among proteins and peptides, and one of the most 
common modification in the process of oxidative folding (Walsh et al. 2005). The formation of 
disulfide bridges can be distinguished into two steps; the oxidation of cysteines to form disulfide 
bridges, and the isomerization of erroneous disulfide bridges to the bona fide pattern (Gleiter and 
Bardwell 2008). For proteins and peptides with more than two cysteine residues, the possibility for 
erroneous disulfide bonding increases rapidly with cysteine count (Gleiter and Bardwell 2008). The 
larger the number of disulfide bridges, the greater the stability of the mature product (in theory) 
(Góngora-Benítez et al. 2013). In bacteria, proteins with disulfide bridges play vital roles in important 
cellular processes, including motility, cell division, virulence factors of pathogenic bacteria, reaction 
to environmental threats, transport of virulence proteins, and outer membrane assembly of Gram-
negative bacteria (Landeta et al. 2018; Figure 9). Disulfide bridges can be oxidized (formed), reduced 
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(broken) or isomerized (shuffled) in the context of protein and peptide folding (Berkmen 2012). In 




Figure 9. Advantages of disulfide bridge. Adapted from Góngora-Benítez et al. (2013). 
 
Disulfide bridges in proteins and peptides are generated through an oxidative process where a 
covalent bond is formed between the sulfur atoms of two cysteines (Heras et al. 2009; Landeta et al. 
2018; Fass and Thorpe 2018; Figure 10). Disulfide bridges can form spontaneously in atmospheric 
conditions but the reaction is slow (Bocian-Ostrzycka et al. 2017). Disulfide bridge formation is an 
enzymatic process and an electron transfer event where a temporary disulfide bridged complex is 
formed between the enzyme and the substrate (Berkmen 2012). Proteins that catalyze disulfide bridge 
formation belong to the large group of thiol-disulfide oxidoreductases (TDORs) found in all living 
cells (Kadokura et al. 2003; Bocian-Ostrzycka et al. 2017). All such proteins have a thioredoxin fold 
and the catalytic site motif CxxC, which is involved in redox reactions (Bardwell et al. 1991; Berkmen 
2012; Landeta et al. 2018). Disulfide bridge formation through oxidative folding by folding catalysts 
is fundamental for the activities of many proteins and peptides, bacterial virulence, proper growth 
and division (Heras et al. 2009; Reardon-Robinson and Ton-That 2016).  
 
 
Figure 10. Oxidation of thiol groups of two cysteines resulting in disulfide bridge. 
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The Dsb family of enzymatic proteins represents a prime example of bacterial oxidative protein 
folding. The first Dsb protein discovered was DsbA from E. coli (Bardwell et al. 1991). DsbA forms 
disulfide bridges to its substrate by a thiol-disulfide exchange reaction via bestowing its disulfide 
bridges to the cysteines of the substrate. DsbB interacts with DsbA, keeping it oxidized and thereby 
active. DsbC and DsbD work as isomerases by repairing incorrect disulfide bridges (Kadokura et al. 
2003; Kadokura and Beckwith 2010; Davey et al. 2016; Landeta et al. 2018; Fass and Thorpe 2018). 
Certain bacterial taxa possess a DsbA homolog while lacking a DsbB homolog. These species, 
including cyanobacteria and actinobacteria, employ a protein belonging to the VKOR family to 
reoxidize the DsbA homolog (Dutton et al. 2008). The active site (CXXC) of the Staphylococcus 
aureus DsbA (SaDsbA) has been shown to be evenly stable in its oxidized and reduced shapes, 
indicating that it does not depend on the DsbB-like protein (Heras et al. 2008). SaDsbA requires 
solely the presence of oxidizing factors to reach the catalytically active form (Heras et al. 2008). 
Another individually operating DsbA-like protein called SdbA has been identified in Streptococcus 
gordonii and shown to be crucial in substrate disulfide bridge formation and a novel type of TDOR 
(Davey et al. 2013). Disulfide bridge formation is a fundamental process in microbial life (Landeta 
et al. 2018) and the burgeoning count of sequenced bacterial genomes has shown that oxidative 
folding mechanisms differ extensively (Heras et al. 2009).  
 
1.7.1.1 Bioactive natural products with disulfide bridge(s)  
 
The formation of disulfide bridges is an important post-translational modification increasing the 
conformational stability of many natural products. Disulfide bridges conserve the macromolecular 
conformation and are vital for the biological activity and stability of peptides, and are therefore 
frequently found in peptide therapeutics (Góngora-Benítez et al. 2013). Examples of disulfide-
containing therapeutic peptides include the anticancer agent romidepsin from Chromobacterium 
violaceum, antibiotic holomycin from Streptomyces clavuligerus, virulence factor gliotoxin from 
Aspergillus fumigatus, peginesatide for the treatment of anemia and linaclotide for the treatment of 
chronic constipation (Góngora-Benítez et al. 2013; Scharf et al. 2014; Fass and Thorpe 2018). 
Disulfide bridges can lock the structure of the peptide into a bioactive conformation. These 
characteristics make cysteine residues and disulfide bridges good tools for improving the 
pharmacological properties of peptides (Góngora-Benítez et al. 2013; Figure 9).  
Defensins are antimicrobial peptides, expressed by animals, fungi and plants for host defence (Ganz 
2003; Shafee et al. 2017). They are small (<10 kDa), cysteine-rich (forming three to six disulfide 
bridges), usually cationic (net charge in the range of +1 to +5) and have low amino acid identity 
(Shafee et al. 2017). Defensins are active against Gram-positive and Gram-negative bacteria, viruses 
and fungi (Ganz 2003; Brogden 2005). Other examples of eukaryotic disulfide bridge peptides are 
cyclotides which are plant defense peptides with three disulfide bridges and exceptional stability (De 
Veer et al. 2019), as well as conotoxins from cone snails with 2–5 disulfide bridges representing 
attractive leads for drug development and neurological applications (Jin et al. 2019).   
Laterosporulins are defensin-like bacteriocins produced by Brevibacillus spp. containing six 
cysteines with conserved positions forming three intramolecular disulfide bridges (Singh et al. 2012; 
Baindara et al. 2016). Other defensin-like bacteriocins include cationic bactofensin (O’Shea et al. 
2013; O’Connor et al. 2018), pediocin-like bacteriocins from which more than 20 peptides have been 
identified (Oppegård et al. 2015) and the recently discovered actifensins within the Actinomyces 
genus (Sugrue et al. 2020). Bioactive peptides with disulfide bridges occur more commonly in 
eukaryotes and infrequently in bacteria. 
29 
 
1.7.2 α-helical peptides  
 
Peptides with an α-helical structure are cationic, and are therefore electrostatically drawn to the 
negatively charged microbial cell membrane (Tossi et al. 2000), which is the main target for the 
majority of cationic antimicrobial peptides (Mokherjee et al. 2020). The structure of a peptide of this 
class indicates that it might function as a pore former in contact with bacterial membranes (Tossi et 
al. 2000; Brogden 2005; Mokherjee et al. 2020; Figure 11). α-helical peptides assume amphipathic 
conformations in three dimensions usually only when in contact with membranes, and otherwise these 
compounds are highly flexible in solution (Hancock and Sahl 2006). Factors that can impact the 
activity and potency of α-helical peptides include the helical content, sequence, charge of the peptide, 
amphipathicity, hydrophobicity, and the widths of the hydrophilic and hydrophobic sites (Tossi et al. 
2000). Modifying one factor can end up in remarkable changes to one or more of the other factors 
(Tossi et al. 2000).  
The antimicrobial magainin peptides from the skin of the African clawed frog Xenopus laevis are 
structurally amphiphilic α-helices (Zasloff 1987). These peptides have been shown to be active 
against fungi, protozoa, and Gram-positive and Gram-negative bacteria (Zasloff 1987). A synthetic 
analog of magainin, Pexiganan, proceeded to phase III clinical trials, targeting the treatment of 
diabetic foot ulcers, but ultimately failed the trials (Fox 2013).  
 
 
Figure 11. Structure of α-helical, amphipathic and charged peptide. Red color indicates hydrophobic, blue 
hydrophilic, and yellow charged amino acid residues. The model was created using a peptide sequence 
(FWGGVFDVLKKAGKGALQGVMS) discovered in this study. The PDB model was created with the 









2 Study aims  
 
Bacteria are prolific sources of structurally divergent natural products, produced employing an array 
of promiscuous natural product enzymes (Fewer and Metsä-Ketelä 2019). The biosynthetic pathways 
of natural products in microorganisms harbor enormous potential for the drug industry and 
biotechnology. The aim of this study was to widen the understanding regarding the biochemical 
diversity of the cyanobactin family of natural products through the following means: i. discovering 
and exploring novel cyanobactin pathways from cyanobacteria and other bacteria; ii. testing the 
biosynthetic boundaries of the cyanobactin class; and iii. characterizing the end-products and 
underlying enzymatic machinery through genome mining. General scheme of this study is presented 
in Figure 12. 
 
3 Summary of materials and methods 
 





Cloning and heterologous expression I-III
Bioinformatic analysis of gene clusters I-III
Mass spectrometry (LC-MS & Q-TOF) I-III
Compound purification I, III
NMR I, III
Cultivation of bacteria I-III
DNA extraction I-III
Stable isotope labeling II
PCR and primer design I-III
Antimicrobial bioassays and MIC II
Protein overexpression I, III






Figure 12. Overview of workflow in this study leading to discovery of new cyanobactin pathways. 
4 Summary of results and discussion 
 
A large mass of genome sequence data has shown that RiPP biosynthetic pathways are much more 
widespread than anticipated (Oman and van der Donk 2010), and an increasing number of structurally 
diverse peptides are emerging from this biosynthetic pathway type (Arnison et al. 2013). The 
cyanobactin pathway has now been studied for approximately 15 years, and with the boom of genome 
sequencing and mining, new enzymes and peptides belonging to the cyanobactin family of natural 
products continue to be discovered. Genome mining is a powerful approach which, if applied 
systematically across the bacterial domain, could greatly expand the known chemical and genetic 








4.1 Discovery and biosynthesis of peptide alkaloids muscoride A and B (I)  
 
Muscoride A was identified from the cyanobacterium Nostoc muscorum IAM M-14 (Nagatsu et al. 
1995), but the BGC for its biosynthesis was not described. The structure of muscoride A (Nagatsu et 
al. 1995) suggests that it might be produced through the cyanobactin biosynthetic pathway. We 
cultivated Nostoc sp. PCC 7906, which is an identical strain to Nostoc muscorum IAM M-14, to 
examine whether it produces muscoride A by LC-MS. We detected muscoride A (m/z 513.3), and 
based on this discovery, we sequenced the genome of Nostoc sp. PCC 7906 to mine and annotate the 
genes for muscoride A BGC (mus). The mus BGC encodes 10 conserved cyanobactin genes and it 
differs from the canonical cyanobactin biosynthetic pathway in key features. The mus BGC encodes 
only one protease and two prenyltransferases. Variants of PatF homologs are encoded in nearly all 
cyanobactin BGCs, but not all cyanobactins are prenylated (Schmidt and Donia 2009; Sivonen et al. 
2010; Gu et al. 2018). 
Bioinformatic analysis of unpublished Nostoc genomes and public databases led to the identification 
of 12 complete mus biosynthetic gene clusters. The precursor proteins encode predicted peptides with 
VPTT, VPTS, IPTS, IPSTS, or IPTSS sequences. The putative muscoride variant (IPSTS) from 
Nostoc sp. UHCC 0398 was subjected to mass spectrometric analysis, and the compound was detected 
(m/z 580.31) from the bacterial crude extract. A sufficient amount of the compound was purified from 
Nostoc sp. UHCC 0398 and subjected to NMR analysis. The 1D and 2D NMR analysis revealed three 
contiguous oxazoles and two prenyl moieties in forward orientation in the amino- and carboxy-
termini of a linear compound, which was named muscoride B (Figure 13).  
Inspection of mus BGCs and the structures of muscoride A & B suggest that MusF1 and MusF2 could 
potentially be regiospecific prenyltransferases. In order to test this hypothesis, we overexpressed the 
MusF1 and MusF2 proteins from Nostoc spp. PCC 7906 and UHCC 0398 and organically synthesized 
the core of the muscoride A backbone without prenyl moieties. Biochemical in vitro assays with 
overexpressed prenyltransferases together with the muscoride A core as a native substrate 
demonstrated the prenyltransferase enzymatic activity of the MusF1 and MusF2 proteins. The MusF1 
enzymes from Nostoc spp. PCC 7906 and UHCC 0398 both catalyze the forward prenylation of the 
carboxy-terminus. The two MusF2 enzymes differ significantly as the MusF2 from Nostoc sp. PCC 
7906 catalyze reverse prenylation whereas MusF2 from Nostoc sp. UHCC 0398 catalyze forward 
prenylation (Figure 13). Both muscoride BGCs were heterologously expressed, which provided 
further support concerning the boundaries of these gene clusters. This study expanded the genetic and 
chemical diversity of the cyanobactin family to include polyoxazole bisprenylated linear peptides, 




Figure 13. mus BGC illustrating regiospecific prenyltransferase activity of MusF1 and MusF2 enzymes. 
 
4.2 Discovery of truncated cyanobactin BGC and unusual cyanobactins (II) 
 
Since the discovery of cyanobactins, genome mining studies have gradually increased the genetic and 
chemical diversity of the family to include linear peptides which are highly modified (Leikoski et al. 
2013). Genome mining was used to identify an unusual truncated cyanobactin BGC distributed across 
the bacterial domain encoding a cyanobactin protease together with 1–8 precursor proteins. The 
protease is encoded as a bimodular protein possessing a peptidase domain and a DUF (Figure 14 A). 
The truncated cyanobactin BGC protease shares about 40 % similarity to known cyanobactin 
proteases (Lee et al. 2009; Agarwal et al. 2012). An inspection of the precursor proteins revealed that 
the predicted cores encode an even number of cysteines, which suggests that they would form 
disulfide bridges (Figure 14 A & D). Disulfide bridge peptides are well known from eukaryotes (Ganz 
2003; Shafee et al. 2017; De Veer et al. 2019; Jin et al. 2019), but rarely reported from bacteria.   
We studied 12 candidate strains (nine cyanobacterial and three other bacterial strains) for the 
expression of bioinformatically predicted disulfide bridge stabilized peptides by LC-MS and Q-TOF. 
Three peptides were discovered by mass spectrometry from Pseudanabaena sp. PCC 6802, and were 
named pseudabactins A–C (data only shown for pseudabactin A) (Figure 14 A). All of these 
structurally novel cyanobactins had four intramolecular disulfide bridges. The cyanobacterium 
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Pseudanabaena sp. PCC 6802 was cultured in medium containing the 34S isotope in order to 
authenticate the number of cysteines encoded in the peptides. Pseudabactin A with a larger mass was 
detected from bacterial crude extract cultured in media with the 34S isotope (Figure 14 B). 
Heterologous expression was performed to demonstrate the boundaries of the gene cluster and that 
the gene cluster is active (Figure 14 C). The truncated cyanobactin BGC was amplified from 
Pseudanabaena sp. PCC 6802 with specific primers, restricted with restriction enzymes, ligated with 
the Puc57 vector to create a recombinant plasmid (p6802NGC), subcloned to E. coli Top10 -cells, 
and further heterologously expressed in E. coli expression strains. The expression level of 
pseudabactin A was higher compared to the native producer Pseudanabaena sp. PCC 6802 (Figure 
14 B). A synthetic construct containing the codon optimized PsbA protease and the PsbE2 precursor 
protein (pseudabactin A) was also constructed to create a recombinant plasmid (p6802OPT). These 
results yielded further support for the existence of disulfide bridge stabilized novel cyanobactins 







Figure 14. A) Truncated cyanobactin BGC from Pseudanabaena sp. PCC 6802 for producing disulfide 
bridge stabilized peptides from which three out of four were detected. B) In the presence of 34S, a mass unit 
addition of 16 Da to pseudabactin A is detected, and when divided by charge (+4), a mass unit difference of 
4 Da is visible. Pseudabactins A with 4 Da larger mass can be seen in the presence of 34S but not in the 
presence of 32S. C) Pseudabactin A detected (m/z 1179) from native producer cyanobacterium (PCC 6802) 
and heterologously expressed in E. coli. D) Model of pseudabactin A with four intramolecular disulfide 
bridges between cysteines representing one hypothetical disulfide connectivity pattern out of 105 possible 
ones. A PDB model of pseudabactin A was created using the iTasser-tool and drawn with Pymol.  
 
Once the production of pseudabactins A–C had been confirmed, more detailed predictions of protease 
cleavage sites could be performed, followed by further genome mining. A subset of peptides was 
identified from the same family without cysteines encoded in their cores (Figure 15). The 
bioinformatic analysis suggested that these peptides would form α-helical structures based on their 
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core sequences (Figure 15). This is a known structure of antimicrobial peptides primarily produced 
by eukaryotes (Tossi et al. 2000: Mokherjee et al. 2020). Some of these peptides were synthesized 
and tested against a panel of bacteria in disc diffusion assays and for their minimal inhibitory 
concentration (MIC). The peptides were shown to be antimicrobial in the concentration range 0.6–
22.5 µM (Table 2). The putative α-helical peptides were not detected from crude extracts from their 
native producer bacterium. The gene clusters for producing these peptides are most likely silent and 
become active when in contact with competing bacterial membranes (Hancock and Sahl 2006). 
 
 
Figure 15. Precursor peptide alignment between detected cysteine-rich pseudabactins A–C (highlighted by 
black rectangle) and predicted cysteine-poor core peptides with supposed α-helical structures from different 
bacterial strains. These precursor peptides have conserved residues in their leader sequences 
(MKLPxQAxxxxR), while the core sequences are more variable. The synthetic analogs of the core peptides 
with supposed α-helical structures were shown to display antimicrobial activity.  
 
























22 11 11 2.8 
Roseibium sp. 
TrichSKD4 B  
 
FWGALASAAAPIAIDLGKKALRGLLR 4.7 2.3  18.6 0.6 
Vibrio 
nigripulchritudo 
SOn1 A  
 
FWGTAFDILKKAGKGALQGVMS ND 10.8 21.5 2.7 
Vibrio 
nigripulchritudo 
SOn1 B  
 
FWGGVFDVLKKAGKGALQGVMS 21.8 10.9 21.8 2.7 
Yersinia 
frederiksenii 
ATCC 33641  
 
FWDSVLSVLKKAGQGALAGVLG ND 22.5 ND 11.3 





The bioinformatic analysis of the DUF suggested that it might function as a disulfide bridge 
generating enzyme. We tested for disulfide bridge formation by replacing the Cys residues with Ala 
residues in the supposed catalytic sites in the DUF (N-terminal CSC site and C-terminal CRPDSDC 
site) and observed the outcome on pseudabactin A expression by Q-TOF (Figure 16). All thiol-
disulfide oxidoreductases have the redox-active catalytic site CxxC, which is involved in disulfide 
bridge redox reactions (Bardwell et al. 1991; Berkmen 2012; Landeta et al. 2018), and we therefore 
hypothesized that one of these sites encoded in the DUF might be redox-active in oxidative folding 
of the substrate peptide pseudabactin A. There was no pseudabactin A production when the N-
terminal Cys-residues were replaced with Ala residues (CSC→ASA), or when the DUF was 
enzymatically deleted (Figure 16). Replacing the Cys residues with Ala residues in the C-terminus 
(CRPDSDC→ARPDSDA) did not abolish pseudabactin A expression but hindered it (Figure 16).  
 
 
Figure 16. A) Site-directed mutagenesis experiments performed on native gene cluster (p6802NGC). DUF 
was enzymatically deleted from the optimized gene cluster (p6802OPT). B) Pseudabactin A production was 
not detected (i. e. disulfide bridge formation did not occur) when supposed catalytic site cysteines were mutated 
(SDM 1) or when the DUF was deleted enzymatically. The mutation of the CX5C-site (SDM 2) hindered 




These results suggest that the DUF is important in disulfide bridge formation in pseudabactin 
biosynthesis. It is tempting to speculate that the DUF of the protease is responsible for disulfide bridge 
formation in the macrocyclic cyanobactins ulithiacyclamide (Ireland and Scheuer 1980) and 
piricyclamides (Leikoski et al. 2012). In conclusion, this study expanded the genetic and chemical 
diversity of the cyanobactin family to include disulfide bridge and α-helical peptides, suggesting that 
the DUF is a potential disulfide bridge generating oxidase, and suggesting re-defining the minimal 
cyanobactin BGC to include only the genes encoding for the protease and precursor(s).  
 
4.3 Biosynthesis of prenylated anacyclamide (III)  
 
Anacyclamides are highly diverse macrocyclic cyanobactins (Leikoski et al. 2010; Leikoski et al. 
2013; Martins et al. 2018). Cyclic anacyclamides consist of 7–20 proteinogenic amino acids and lack 
heterocyclized residues in their structure (Leikoski et al. 2010). The anacyclamide BGC from 
Anabaena sp. UHCC 0232 encompasses AcyA, AcyB, AcyC, AcyE, AcyF, AcyG, and an additional 
two open reading frames (ORFs) with unclear functions in anacyclamide biosynthesis (Figure 17). 
The PTMs for the AcyE core (HQPWHAAP) include proteolytic cleavage, macrocyclization and 
prenylation (Leikoski et al. 2010). The cyanobacterium Anabaena sp. UHCC 0232 was cultivated 
and its methanol extract was analyzed by LC-MS. It was shown that Anabaena sp. UHCC 0232 
produces the prenylated anacyclamide A8P (m/z 993.50), as reported previously (Leikoski et al. 
2010). The successful heterologous expression of the acy gene cluster confirmed the boundaries of 
the gene cluster. However, detection of anacyclamide by mass or heterologous expression could not 
unequivocally designate the orientation or the position of the prenyl moiety.   
KgpF is a Trp C-prenyltransferase from the biosynthetic pathway of the cyanobactin kawaguchipeptin 
(Parajuli et al. 2016; Okada et al. 2016). We hypothesized that AcyF is a Trp N-prenyltransferase 
from the biosynthetic pathway of the cyanobactin anacyclamide. A two-plasmid expression system 
was constructed to compare the functions of AcyF and KgpF. A minimal acy gene cluster encoding 
AcyA–AcyG was constructed to produce the pABCFG plasmid. The plasmid pSYNE was 
constructed by replacing the native anacyclamide HQPWHAAP core with the kawaguchipeptin 
WLNGDNNWSTP core sequence. Simultaneous expression of these two plasmids in E. coli BL21 
resulted in the detection of bisprenylated peptides with the same mass as kawaguchipeptin A with the 
enzymatic machinery from the anacyclamide (acy) biosynthetic pathway. Kawaguchipeptins 
produced by the kgp pathway (Parajuli et al. 2016) had different retention times compared to the 
bisprenylated kawaguchipeptin produced by the acy pathway. This result suggests that there are likely 
to be regioselective prenylation differences between the acy and kgp biosynthetic pathways.  
AcyF was overexpressed in order to further examine the catalytic activity of this putative Trp N-
prenyltransferase in biochemical assays. The anacyclamide A10 core (cyclo [TSQIWGSPVP]) 
(Leikoski et al. 2010), already as synthetic in our lab, was expected to be an applicable substrate for 
the AcyF enzyme. An in vitro assay was performed where the AcyF was mixed together with the 
substrate and DMAPP as a donor substrate, and analyzed by LC-MS. The mass of the substrate 
increased by 68.06 Da suggesting the incorporation of a prenyl moiety to the compound. The whole 
reaction was scaled up, and the reaction product was purified using HPLC and subjected to NMR. 
NMR analysis was performed to acquire firm evidence of the position in the indole ring of Trp and 
the orientation of the prenyl moiety. The prenyltransferase AcyF was able to prenylate protected Trp 
derivatives, z-Trp-OH and Boc-Trp-OH, as well. The analysis demonstrated that the prenyl group is 
attached to the Trp indole ring nitrogen in forward orientation. In this study, the AcyF regiospecific 
prenyltransferase from the cyanobactin biosynthetic pathway of Anabaena sp. UHCC 0232 was 








This thesis demonstrates that the cyanobactin family of natural product peptides is much more widely 
distributed and structurally diverse than currently appreciated. Genome mining combined with mass 
spectrometric methods, molecular biology, biochemical assays and structural chemistry has provided 
us with insights on cyanobactin biosynthesis.  
Cyanobactin biosynthesis involves multiple post-translational modifications leading to an astonishing 
array of compounds. This work has increased knowledge regarding the enzymology of cyanobactin 
biosynthetic pathways, as well as discovering novel post-translational modification enzymes and 
structurally novel cyanobactins. We have identified regiospecific prenyltransferases and a 
hypothetical disulfide bridge generating enzyme. The study has broadened the chemical diversity of 
cyanobactins to include bis-prenylated polyoxazole linear peptides, disulfide bridge stabilized 
peptides, and α-helical peptides as products from cyanobactin pathways. Together the results of this 
PhD thesis expand the cyanobactin family considerably and will affect how cyanobactins are 
determined in the future. Cyanobactin pathways are an abundant source of modification enzymes and 
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